Chiasma — Technical Presentation (November 2020)
12 slides from Chiasma's technical presentation, Nov 18, 2020
Slide 1: Phase 3 MPOWERED Trial Top-line Results
Phase 3 MPOWEREDTM Trial Top-line Results November 18, 2020 Exhibit 99.1
Slide 2: Forward-looking statements
These slides and the accompanying presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expression
Slide 3: MYCAPSSA is FDA Approved and is Commercially Available in the U.S.
MYCAPSSA is FDA Approved and is Commercially Available in the U.S. Full prescribing information available at www.MYCAPSSA.com MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreo
Slide 4: Acromegaly Market Overview
Acromegaly Market Overview Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments Acromegaly is a rare disease most often caused by a benign pituitary tumor and characterized by an excess of growth hormone and insulin-like growth factor-1 hormone. Treatment op
Slide 5: Injections Carry Significant Treatment Burdens
experience pain during injection; half of these experienced continuing pain days later Injections Carry Significant Treatment Burdens1 Pain Suboptimal Symptom Control Lost Workdays Emotional Impact Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammatio
Slide 6: MPOWERED Trial Positive: Met Primary Non-inferiority Endpoint
MPOWERED Trial Positive: Met Primary Non-inferiority Endpoint MYCAPSSA (octreotide capsules) was shown to be non-inferior to long-acting injectable somatostatin analog injections (SSAs)* in maintenance of biochemical response for acromegaly patients. * Octreotide LAR and lanreotide autogel
Slide 7: MPOWERED Non-inferiority Study Design
MPOWERED Non-inferiority Study Design Last Injection Day (-28) Screening First Dose 6-Month Run-in Phase Responders Randomized to 9-Month Controlled Phase (RCT) Open Label Extension Follow for safety and efficacy 60% (55 pts) 40% (37 pts) Non-Responder Sub-study or Non-Responders Screening phase up
Slide 8: Higher Baseline IGF-1 Levels in the MYCAPSSA Arm Compared to Injectable SSA Arm
Higher Baseline IGF-1 Levels in the MYCAPSSA Arm Compared to Injectable SSA Arm MYCAPSSA Injectable Long-acting SSAs Total (N=55) Total (N=37) Week 26 IGF-1 (categorical) (n [%]) ≤ 1 x ULN 37 (67%) 29 (78%) > 1 to < 1.3 x ULN 12 (22%) 8 (22%) ≥ 1.3 x ULN 6 (11%) 0 (0%) Week 26 IGF-1 (ULN) Mean (SD)
Slide 9: MYCAPSSA is Non-inferior to Long-acting Injectable SSAs
MYCAPSSA is Non-inferior to Long-acting Injectable SSAs Achieved the pre-specified non-inferiority margin of -20% Primary Endpoint: IGF-1 Time Weighted Average (TWA)1 throughout the RCT phase < 1.3 x ULN 1 TWA response represents an integrated measure of efficacy across time. It is derived as the ar
Slide 10: Mean IGF-1 Levels Were Maintained Within Normal Limits
Mean IGF-1 Levels Were Maintained Within Normal Limits Baseline of RCT Baseline of RCT End of Treatment End of Treatment
Slide 11: MYCAPSSA Appeared to be Safe and Well Tolerated
MYCAPSSA Appeared to be Safe and Well Tolerated MYCAPSSA Injectable Long-acting SSAs Subjects with: n % n % At least one TEAE 39 70.9 26 70.3 Treatment-Related TEAE 19 34.5 15 40.5 SAEs 3 5.5 3 8.1 Severe TEAEs 5 9.1 4 10.8 TEAE Leading to Study Drug Discontinuation(1) 1 1.8 0 0 SAEs - Serious Adver
Slide 12: MYCAPSSA Appeared Safe and Well Tolerated
MYCAPSSA Appeared Safe and Well Tolerated MYCAPSSA Injectable Long Acting SSAs Total (N=55) Total (N=37) Gastrointestinal disorders Flatulence 14 (25.5) 8 (21.6) Nausea 11 (20.0) 3 (8.1) Diarrhea 6 (10.9) 5 (13.5) Abdominal pain 5 (9.1) 3 (8.1) Constipation 3 (5.5) 5 (13.5) Infections & infestations